Project Grant R21NS135529

Award Date 9/1/24
Completion Date 8/31/26
Dollars Obligated $448K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Richardson, TX 75080, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders federal grant program (CFDA 93.853), will provide $123,616.00 to investigate the role of the blood-brain barrier in the trafficking of prenatal liver-derived immune cells into the brain. The research aims to elucidate the cellular and molecular development of the blood-brain barrier and its impact on cellular...
This $437,250 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to compare the gene expression of the key cell types that form the blood-nerve barrier (BNB) in the peripheral nervous system and the blood-brain barrier (BBB) in the central nervous system under physiological conditions. The research will also...
This federal Project Grant award of $377,875 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to develop a "one-two punch" strategy using engineered extracellular vesicles (EVs) to protect the blood-brain barrier (BBB) and improve outcomes in stroke. The primary goals are to: 1) deliver ATP5A and HSP27 proteins via the EVs to increase endothelial...
This Project Grant award of $534,964.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund the development of an in vitro platform to investigate the role of matrix metalloproteinase-9 (MMP-9) in the breakdown of the blood-brain barrier and extracellular matrix in multiple sclerosis. The research team at Michigan State University will integrate real-time...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders will support research to understand the mechanisms underlying brain-immune interactions at the blood-brain barrier. The overarching goal is to generate novel targets for immunotherapy in neuroinflammatory conditions. The $230,580 award to Brigham & Women's Hospital, a subsidiary of Partners...
This Project Grant award of $427,625 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop tools for studying proteome plasticity in brain endothelial cells. The goal is to elucidate the mechanisms by which changes in neuronal energy demands lead to reprogramming of signaling pathways that control brain blood flow, which is critical for...
This Cooperative Agreement award, provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is funding the development of novel lipid nanoparticles (LNPs) for delivering nucleic acid-based therapeutics to the brain. The total award amount is $843,806.00 and the project period runs from April 10, 2025 to March 31, 2030. The goal of this project is to...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $465,752 to the Regents of the University of Michigan - Dearborn to conduct research on understanding changes in cell chirality and cell-cell interactions within the neurovascular unit (NVU) after traumatic brain injury (TBI). The project aims to evaluate TBI-induced...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders" provides $404,100.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study the mechanisms of chronic blood-brain barrier dysfunction after traumatic brain injury (TBI). The research aims to identify a signaling pathway involving the...
This federal Project Grant award of $221,120.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to improve neural progenitor (NP) survival and migration for the treatment of neurodegenerative diseases and brain injuries. The project investigates the potential of adult central nervous system (CNS) endothelial cells to express developmental...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the federal Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to establish the feasibility of cell-type specific modulation of the blood-brain barrier (BBB) using a novel "MagnetoBBB" approach. The total award amount is $447,501.00 with a project period from September 1, 2024 to August 31, 2026.

The key objectives are to: 1) Investigate and optimize BBB control using a human brain microvascular endothelial cell line in vitro, including characterizing calcium signaling and measuring changes in electrical resistance and permeability across the cell monolayer; and 2) Study the ability to control BBB permeability in the rodent brain in vivo by delivering FERIC genes into microvascular endothelial cells and investigating the magnetic field requirements. The project leverages the University of Texas at Dallas as the primary grantee and includes a $74,756.00 sub-award to the University of California, Berkeley to develop FERIC plasmids and conduct in vitro/ex vivo experiments.

Generated 7/1/25, 2:27 AM